BACKGROUND: Cognitive complications persist in persons with HIV during suppressive antiretroviral therapy (ART). Low levels of HIV during ART could contribute to these complications. In this study, we measured cerebrospinal fluid (CSF) HIV using a single-copy assay (SCA) to investigate a possible relationship between low-level HIV and cognition. DESIGN/ METHODS: SCA data were analyzed from 3 consecutively paired CSF-plasma specimens collected over a mean of 456 days from 96 participants on suppressive ART. Using mixed models, the presence of CSF HIV by SCA as a risk factor for worse neurocognitive performance was examined. RESULTS: At baseline on the SCA, 45.8% of participants had detectable plasma HIV RNA (median 8 copies/mL and interquartile range = 3-17 among detectable values) and 17.7% had detectable CSF HIV RNA (median CSF concentration= 3 copies/mL and interquartile range= 2-13 among detectable values). The frequency of CSF HIV RNA detection declined over time in CSF (P = 0.018) with a trend toward decline in plasma (P = 0.064). Detectable CSF HIV RNA during the study was associated with worse performance in the domains of recall (P = 0.014) and motor (P = 0.040) and a trend with worse overall global performance (P = 0.078). Integrase inhibitor use, although very infrequent in this cohort, was associated with better performance in 2 domains. CONCLUSIONS: Low-level CSF HIV RNA declines with time but is associated with worse cognitive performance in 2 domains. Additional research is needed to better understand the relationship between HIV RNA persistence during long-term ART and central nervous system complications in persons with HIV.
BACKGROUND: Cognitive complications persist in persons with HIV during suppressive antiretroviral therapy (ART). Low levels of HIV during ART could contribute to these complications. In this study, we measured cerebrospinal fluid (CSF) HIV using a single-copy assay (SCA) to investigate a possible relationship between low-level HIV and cognition. DESIGN/ METHODS: SCA data were analyzed from 3 consecutively paired CSF-plasma specimens collected over a mean of 456 days from 96 participants on suppressive ART. Using mixed models, the presence of CSF HIV by SCA as a risk factor for worse neurocognitive performance was examined. RESULTS: At baseline on the SCA, 45.8% of participants had detectable plasma HIV RNA (median 8 copies/mL and interquartile range = 3-17 among detectable values) and 17.7% had detectable CSF HIV RNA (median CSF concentration= 3 copies/mL and interquartile range= 2-13 among detectable values). The frequency of CSF HIV RNA detection declined over time in CSF (P = 0.018) with a trend toward decline in plasma (P = 0.064). Detectable CSF HIV RNA during the study was associated with worse performance in the domains of recall (P = 0.014) and motor (P = 0.040) and a trend with worse overall global performance (P = 0.078). Integrase inhibitor use, although very infrequent in this cohort, was associated with better performance in 2 domains. CONCLUSIONS: Low-level CSF HIV RNA declines with time but is associated with worse cognitive performance in 2 domains. Additional research is needed to better understand the relationship between HIV RNA persistence during long-term ART and central nervous system complications in persons with HIV.
Authors: Serena Spudich; Kevin R Robertson; Ronald J Bosch; Rajesh T Gandhi; Joshua C Cyktor; Hanna Mar; Bernard J Macatangay; Christina M Lalama; Charles Rinaldo; Ann C Collier; Catherine Godfrey; Joseph J Eron; Deborah McMahon; Jana L Jacobs; Dianna Koontz; Evelyn Hogg; Alyssa Vecchio; John W Mellors Journal: J Clin Invest Date: 2019-07-15 Impact factor: 14.808
Authors: M D Hughes; V A Johnson; M S Hirsch; J W Bremer; T Elbeik; A Erice; D R Kuritzkes; W A Scott; S A Spector; N Basgoz; M A Fischl; R T D'Aquila Journal: Ann Intern Med Date: 1997-06-15 Impact factor: 25.391
Authors: S Staprans; N Marlowe; D Glidden; T Novakovic-Agopian; R M Grant; M Heyes; F Aweeka; S Deeks; R W Price Journal: AIDS Date: 1999-06-18 Impact factor: 4.177
Authors: Ronald J Ellis; Scott Letendre; Florin Vaida; Richard Haubrich; Robert K Heaton; Ned Sacktor; David B Clifford; Brookie M Best; Susanne May; Anya Umlauf; Mariana Cherner; Chelsea Sanders; Craig Ballard; David M Simpson; Cheryl Jay; J Allen McCutchan Journal: Clin Infect Dis Date: 2013-12-18 Impact factor: 9.079
Authors: Rajesh T Gandhi; Robert W Coombs; Ellen S Chan; Ronald J Bosch; Lu Zheng; David M Margolis; Sarah Read; Beatrice Kallungal; Ming Chang; Erin A Goecker; Ann Wiegand; Mary Kearney; Jeffrey M Jacobson; Richard D'Aquila; Michael M Lederman; John W Mellors; Joseph J Eron Journal: J Acquir Immune Defic Syndr Date: 2012-03-01 Impact factor: 3.731
Authors: Lucette A Cysique; Donald Franklin; Ian Abramson; Ronald J Ellis; Scott Letendre; Ann Collier; David Clifford; Benjamin Gelman; Justin McArthur; Susan Morgello; David Simpson; J Allen McCutchan; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2011-03-07 Impact factor: 2.475
Authors: Brookie M Best; Scott L Letendre; Eileen Brigid; David B Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; David M Simpson; Ronald Ellis; Edmund V Capparelli; Igor Grant Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin Journal: J Clin Microbiol Date: 2003-10 Impact factor: 5.948